Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …

Substantial improvements have been made in the management of metastatic colorectal
cancer over the last two decades. The overall survival of patients diagnosed with …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many
new treatment methods have been developed during recent decades. The Japanese …

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest
number of deaths from malignant neoplasms among women and the third largest number …

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …

Over the past 60 years, chemotherapeutic agents that target thymidylate biosynthesis and
the enzyme thymidylate synthase (TS) have remained among the most-successful drugs …